Meeting Format: Virtual Meeting.

Contact Person: Gagan Deep Bajaj, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 402–6965, *gagan.bajaj@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Clinical Care, Treatment and Health Interventions.

Date: December 10, 2026.

Time: 9:30 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Shiyong Huang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, (301) 451–7350, *shiyong.huang@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Biomaterials, Nanotechnology, Drug Discovery, and Delivery.

Date: December 10, 2026.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Shakeel Ahmad, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 276–6442, *ahmads@mail.nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Emerging Vision Assistive Technologies.

Date: December 10, 2026.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Susan Gillmor, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 762–3076, *susan.gillmor@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Pregnancy Neonatology Gametes Reproduction Toxicology.

Date: December 10, 2026.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Ryan G. Morris, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, RM 721–B, Bethesda, MD 20892, (301) 451–1322, *ryan.morris@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Basic Cancer Immunobiology and Tumor Host Interactions.

Date: December 11, 2026.

Time: 9:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Angela Y. Ng, MBA, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 710–C, MSC 7806 Bethesda, MD 20892, (301) 435–1715, *nga@csr.nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33).

Date: December 11, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Lan Tian, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–8877, *tianl@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Neurobehavioral Mechanisms of Addiction, Emotion, and Development.

Date: December 11, 2026.

Time: 10:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Anna Ghambaryan, Ph.D., MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 443–4032, *anna.ghambaryan@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 16, 2026.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–23536 Filed 11–18–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Statement of Organization, Functions, and Delegations of Authority

AGENCY: National Institute of Health.

ACTION: Notice.

SUMMARY: National Center for the Advancement of Translational Sciences of the National Institute of Health has modified its organizational structure.

SUPPLEMENTARY INFORMATION: Part N, National Institutes of Health (NIH), of the Statement of Organization and Functions for the Department of Health and Human Services (HHS), is amended as set forth below to reflect the reorganization of the National Institute of Health, National Center for the Advancement of Translational Science (NCATS) by retitling and updating the functional Statements (1) the Chemical Genomics Branch to the Translational Models Branch under the Division of Preclinical Innovation within NCATS, (2) revise functional statement of the Office of Special initiatives, (3) abolishing the Office of Drug Development Partnership Programs, and the Office of Translational Medicine under the Office of the Director within NCATS.

Section N, *Organization and Functions,* is amended as follows:

(1) In the *Division of Preclinical Innovation (N92, formerly HN92)* retitle the following:

Chemical Genomics Branch (N924, formerly HN924) to *Translational Models Branch (N924, formerly HN924).* (1) Develop and advance human-based Non-Animal Models (NAMs) as transformative drug discovery and biomedical research tools; (2) Accelerate therapeutic discovery and regulatory science for rare and common diseases using predictive human model systems; (3) Accelerate target discovery using predictive human model systems; (4) Establish the predictive value and usefulness of human-based NAMs as pharmacology and toxicology assessment tools to reduce reliance on animal models; (5) Generate high-quality human biological data to enable AI-driven predictive modeling of drug efficacy and toxicity; (6) Integrate stem cells, tissue engineering, functional genomics, toxicology and data science into a unified human-based translational research enterprise; and (7) Serve as an NIH-wide resource for advancing human-based models research and technologies.

(2) *In the Office of the Director (N91, formerly HN91)* revise functional statement of the following:

Office of Special Initiatives (N917, formerly HN917). (1) Provides transformative programs extramurally that address barriers and bottlenecks to pre-clinical and clinical translation; (2) Drives development and dissemination of novel and disruptive technologies, approaches, and solutions for issues that impede translational research through promotion to the scientific, research, and industry sectors; (3) Incentivizes groundbreaking expansion of the therapeutic landscape for rare and chronic diseases through discovery and exploration of novel therapeutic targets and programs; and (4) Promotes and engenders partnerships and interagency collaborations with key stakeholders including government, industry, and academia, to advance innovation in early-stage clinical trials.

(3) In the *Office of the Director (N91, formerly HN91)* remove the following:

- *Office of Drug Development Partnership Programs (N918, formerly HN918)*
- *Office of Translational Medicine (N919, formerly HN919)*

Authority: 44 U.S.C. 3101

Robert F. Kennedy, Jr.,

Secretary, Department of Health and Human Services.

[FR Doc. 2026–23537 Filed 11–18–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Partially Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the NIH National Advisory Neurological Disorders and Stroke Council.

The meeting will be partially open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend as well as those who need special assistance, such as sign language interpretation or other reasonable accommodations, must notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (*https://videocast.nih.gov/*).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Neurological Disorders and Stroke Council.

Date: May 19–20, 2027.

Open: May 19, 2027, 10:00 a.m. to 4:00 p.m.

Agenda: Report by the Acting Director, NINDS; Report by the Director, Division of Extramural Activities; and Administrative and Program Developments; HEAL update; State of Intramural Program; To discuss upcoming Concept Clearance Initiatives and other business of the Council.

Address: National Institutes of Health, Neuroscience Center, Room 1131, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual and In-Person Meeting

Closed: May 19, 2027, 4:00 p.m. to 5:30 p.m.; May 20, 2027, 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Neuroscience Center, Room 1131, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual and In-Person Meeting.

Contact Person: Andrea Lynn Meredith, Ph.D. Director of Extramural Activities, National Institute of Neurological Disorders and Stroke, NIH, DHHS, Neuroscience Center, 6001 Executive Boulevard Bethesda, MD 20892, (301) 496–9248, *andrea.meredith@nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice at least 10 days in advance of the meeting. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at *https://www.nih.gov/about-nih/visitor-information/campus-access-security* for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: *www.ninds.nih.gov,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: November 16, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–23534 Filed 11–18–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Council on Parkinson's Research, Care, and Services (ACPRCS).

This is the fourth meeting of the ACPRCS, which was established by the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act of 2024 (Pub. L. 118–66). The Advisory Council is charged with providing advice to the Secretary of Health and Human Services (HHS) on issues that affect people with Parkinson's and related disorders (PDRDs), which include progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, and Lewy body dementias.

The meeting will focus on strategies to provide timely and responsive care to PDRD patients, including how care teams can improve care across settings. The meeting is virtual and will be open to the public to view via HHS Live Streaming: *www.hhs.gov/live.* Registration is not required.

Name of Committee: Advisory Council on Parkinson's Research, Care, and Services (ACPRCS).

Date: December 7, 2026.

Time: 9:00 a.m. to 5:30 p.m.

Agenda: Improving care for Parkinson's and related disorders; public comments; discussion and next steps for PDRD priorities.

Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual Meeting.

Cost: The meeting is free and open to the public.

Deadlines: Public Comment Due Date: November 30th by 5:00 p.m. ET. For public comment instructions and guidelines, see below.

Contact Person: Jordan Gladman, Ph.D., Deputy Executive Officer, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, *nationalPDplan@nih.gov.*